The changing face of HDAC inhibitor depsipeptide

Current Cancer Drug Targets

Volumn 9, Issue 1, 2009, Pages 91-100

  Zhou, Wen ^a   Zhu, Wei Guo ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Depsipeptide; HDAC inhibitor; Histone deacetylase; SAHA; TSA

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 CARBOXYCINNAMIC ACID BISHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; 6 (3 CHLOROPHENYLUREIDO)CAPROIC HYDROXAMIC ACID; 7 [4 (4 CYANOPHENYL)PHENOXY]HEPTANOHYDROXAMIC ACID; A 1619006; APICIDIN; BUTYRIC ACID; CHAP 31; CHAP 50; CYTARABINE; HISTONE DEACETYLASE INHIBITOR; JMJ 16241199; JNJ 16241199; KETONE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PIVALOYLOXYMETHYL BUTYRATE; PROTEIN P53; PYROXAMIDE; ROMIDEPSIN; TRAPOXIN A; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CARDIOTOXICITY; CHELATION; CHEMOTHERAPY INDUCED EMESIS; CHROMATIN; CLINICAL TRIAL; COLORECTAL CANCER; CREATINE KINASE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DEMETHYLATION; DNA METHYLATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ECG ABNORMALITY; ENZYME INHIBITION; FATIGUE; GENE REPRESSION; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOCALCEMIA; IC 50; KIDNEY CARCINOMA; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METABOLIC REGULATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PERIPHERAL T CELL LYMPHOMA; PROSTATE CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; ST SEGMENT; T WAVE INVERSION; THROMBOCYTOPENIA; THYROID CARCINOMA; TRANSCRIPTION INITIATION;

ACETYLATION; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; OLIGOPEPTIDES; PROTEIN CONFORMATION;

EID: 62549143972     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909787314039     Document Type: Review

References (112)

1. Karamouzis, M. V.; Gorgoulis, V. G.; Papavassiliou, A. G. Transcription Factors and Neoplasia: Vistas in Novel Drug Design. Clin. Cancer Res. 2002, 8, 949-961.
2. Marks, P. A.; Richon, V. M.; Rifkind, R. A. Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells. J. Natl. Cancer Inst. 2000, 92, 1210-1216.
3. Elsayed, Y. A.; Sausville, E. A. Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins. Oncologist 2001, 6, 517-537.
4. Acharya, M. R.; Sparreboom, A.; Venitz, J.; Figg, W. D. Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review. Mol. Pharmacol. 2005, 68, 917-932.
5. Imming, P.; Sinning, C.; Meyer, A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 2006, 5, 821-834.
6. Lin, H. -Y.; Chen, C. -S.; Lin, S. -P.; Weng, J. -R.; Chen, C. -S. Targeting histone deacetylase in cancer therapy. Medicinal Res. Rev. 2006, 26, 397-413.
7. Van Lint, C.; Emiliani, S.; Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hy-peracetylation. Gene Expr. 1996, 5, 245-253.
8. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases. Cancer Res. 2002, 62, 4916-4921.
9. Zhu, W.-G.; Lakshmanan, R. R.; Beal, M. D.; Otterson, G. A. DNA Methyltransferase Inhibition Enhances Apoptosis Induced by His-tone Deacetylase Inhibitors. Cancer Res. 2001, 67, 1327-1333.
10. Adachi, M.; Zhang, Y.; Zhao, X.; Minami, T.; Kawamura, R.; Hinoda, Y.; Imai, K. Synergistic Effect of Histone Deacetylase Inhibitors FK228 and m-Carboxycinnamic Acid Bis-Hydroxamide with Proteasome Inhibitors PSI and PS-341 against Gastrointestinal Adenocarcinoma Cells. Clin. Cancer Res. 2004, 10, 3853-3862.
11. Piekarz, R. L.; Frye, A. R.; Wright, J. J.; Steinberg, S. M.; Liewehr, D. J.; Rosing, D. R.; Sachdev, V.; Fojo, T.; Bates, S. E. Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma. Clin. Cancer Res. 2006, 12, 3762-3773.
12. Wu, L. -P.; Wang, X.; Li, L.; Zhao, Y.; Lu, S.; Yu, Y.; Zhou, W.; Liu, X.; Yang, J.; Zheng, Z.; Zhang, H.; Feng, J.; Yang, Y.; Wang, H.; Zhu, W. -G. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promotor. Mol. Cell Biol. 2008, 28, 3219-3235.
13. Vaquero, A.; Loyola, A.; Reinberg, D. The Constantly Changing Face of Chromatin. Sci. Aging Knowl. Environ. 2003, 14, re4.
14. Fuks, F. DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 2005, 15, 490-495.
15. Kornberg, R. D.; Lorch, Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999, 98, 285-294.
16. Luger, K.; Mader, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 1997, 389, 251-260.
17. Khorasanizadeh, S. The nucleosome: from genomic organization to genomic regulation. Cell 2004, 116, 259-272.
18. Ting, A. H.; McGarvey, K. M.; Baylin, S. B. The cancer epige-nome-components and functional correlates. Genes Dev. 2006, 20, 3215-3231.
19. Kornberg, R. D.; Lorch, Y. Chromatin and transcription: where do we go from here. Curr. Opin. Genet. Dev. 2002, 12, 249-251.
20. Roberts, S. G. Mechanisms of action of transcription activation and repression domains. Cell Mol. Life Sci. 2000, 57, 1149-1160.
21. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Oncologist 2007, 12, 1247-1252.
22. Di Croce, L. Chromatin modifying activity of leukaemia associated fusion proteins. Hum. Mol. Genet. 2005, 14, R77-R84.
23. Hunter, T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol. Cell 2007, 28, 730-738.
24. Elgin, S. C.; Workman, J. L. Chromosome and expression mechanisms: a year dominated by histone modifications, transitory and remembered. Curr. Opin. Genet. Dev. 2002, 12, 127-129.
25. Barnes, P. J.; Adcock, I. M.; Ito, K. Histone acetylation and deace-tylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005, 25, 552-563.
26. Jenuwein, T.; Allis, C. D. Translating the Histone Code. Science, 2001, 293, 1074-1080.
27. Laird, P. W. Cancer epigenetics. Hum. Mol. Genet. 2005, 14, R65-R76.
28. Allis, C. D.; Berger, S. L.; Cote, J.; Dent, S.; Jenuwien, T.; Kouzarides, T.; Pillus, L.; Reinberg, D.; Shi, Y.; Shiekhattar, R.; Shilatifard, A.; Workman, J.; Zhang, Y. New nomenclature for chromatin-modifying enzymes. Cell 2007, 131, 633-636.
29. Ooi, L.; Wood, I. C. Chromatin crosstalk in development and disease: lessons from REST. Nat. Rev. Genet. 2007, 8, 544-554.
30. Glozak, M. A.; Seto, E. Histone deacetylases and cancer. Oncogene 2007, 26, 5420-5432.
31. Gray, S. G.; Ekstrom, T. J. The human histone deacetylase family. Exp. Cell Res. 2001, 262, 75-83.
32. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deacety- lases: versatile regulators. Trends Genet. 2003, 19, 286-293.
33. Forsburg, S. L. Eukaryotic MCM Proteins: Beyond Replication Initiation. Microbiol. Mol. Biol. Rev. 2004, 68, 109-131.
34. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 2004, 73, 417-435.
35. Michishita, E.; Park, J. Y.; Burneskis, J. M.; Barrett, J. C.; Hori-kawa, I. Evolutionarily Conserved and Nonconserved Cellular Localizations and Functions of Human SIRT Proteins. Mol. Biol. Cell 2005, 16, 4623-4635.
36. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5, 37-50.
37. Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Nishimura, M.; Goto, T.; Okuhara, M. FR901228, a novel antitumor bicyclic depsipep-tide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 1994, 47, 301-310.
38. Shigematsu, N.; Ueda, H.; Takase, S.; Tanaka, H.; Yamamoto, K.; Tada, T. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J. Antibiot. (Tokyo) 1994, 47, 311-314.
39. Ueda, H.; Manda, T.; Matsumoto, S.; Mukumoto, S.; Nishigaki, F.; Kawamura, I.; Shimomura, K. FR901228, a novel antitumor bi-cyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo) 1994, 47, 315-323.
40. Li, K. W.; Wu, J.; Xing, W.; Simon, J. A. Total Synthesis of the Antitumor Depsipeptide FR-901,228. J. Am. Chem. Soc. 1996, 118, 7237-7238.
41. Xiao, J. -J.; Byrd, J.; Marcucci, G.; Grever, M.; Chan, K. K. Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun. Mass Spectrom. 2003, 17, 757-766.
42. Rooseboom, M.; Commandeur, J. N. M.; Vermeulen, N. P. E. Enzyme-Catalyzed Activation of Anticancer Prodrugs. Pharmacol. Rev. 2004, 56, 53-102.
43. Cheng, Y. -Q.; Yang, M.; Matter, A. M. Characterization of a Gene Cluster Responsible for the Biosynthesis of Anticancer Agent FK228 in Chromobacterium violaceum No. 968. Appl. Environ. Microbiol. 2007, 73, 3460-3469.
44. Nakajima, H.; Kim, Y. B.; Terano, H.; Yoshida, M.; Horinouchi, S. FR901228, a potent antitumor antibiotic, is a novel histone deace-tylase inhibitor. Exp. Cell Res. 1998, 241, 126-133.
45. Ueda, H.; Nakajima, H.; Hori, Y.; Goto, T.; Okuhara, M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 1994, 58, 1579-1583.
46. Oskarsson, T.; Essers, M. A. G.; Dubois, N.; Offner, S.; Dubey, C.; Roger, C.; Metzger, D.; Chambon, P.; Hummler, E.; Beard, P.; Trumpp, A. Skin epidermis lacking the c-myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev. 2006, 20, 2024-2029.
47. Esteva, F. J.; Valero, V.; Pusztai, L.; Boehnke-Michaud, L.; Buzdar, A. U.; Hortobagyi, G. N. Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. Oncologist 2001, 6, 133-146.
48. Yu, X.; Guo, Z. S.; Marcu, M. G.; Neckers, L.; Nguyen, D. M.; Chen, G. A.; Schrump, D. S. Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228. J. Natl. Cancer Inst. 2002, 94, 504-513.
49. Zhao, Y.; Lu, S.; Wu, L.; Chai, G.; Wang, H.; Chen, Y.; Sun, J.; Yu, Y.; Zhou, W.; Zheng, Q.; Wu, M.; Otterson, G. A.; Zhu, W.-G. Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1. Mol. Cell. Biol. 2006, 26, 2782-2790.
50. Lambert, P. F.; Kashanchi, F.; Radonovich, M. F.; Shiekhattar, R.; Brady, J. N. Phosphorylation of p53 Serine 15 increases Interaction with CBP. J. Biol. Chem. 1998, 273, 33048-33053.
51. Fuster, J. J.; Sanz-Gonzalez, S. M.; Moll, U. M.; Andres, V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol. Med. 2007, 13, 192-199.
52. May, P.; May, E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999, 18, 7621-36.
53. Resnick-Silverman, L.; Manfredi, J. J. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J. Cell. Biochem. 2006, 99, 679-689.
54. Sharpless, N. E.; DePinho, R. A. p53: good cop/bad cop. Cell 2002, 110, 9-12.
55. Barlev, N. A.; Liu, L.; Chehab, N. H.; Mansfield, K.; Harris, K. G.; Halazonetis, T. D.; Berger, S. L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltrans-ferases. Mol. Cell 2001, 8, 1243-1254.
56. Mills, A. A. p53: link to the past, bridge to the future. Genes Dev. 2005, 19, 2091-2099.
57. Fouladi, M.; Furman, W. L.; Chin, T.; Freeman, B. B., III; Dudkin, L.; Stewart, C. F.; Krailo, M. D.; Speights, R.; Ingle, A. M.; Houghton, P. J.; Wright, J.; Adamson, P. C.; Blaney, S. M. Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report. J. Clin. Oncol. 2006, 24, 3678-3685.
58. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
59. Levine, A. J.; Momand, J.; Finlay, C. A. The p53 tumour suppressor gene. Nature 1991, 351, 453-456.
60. McKinney, K.; Mattia, M.; Gottifredi, V.; Prives, C. p53 linear diffusion along DNA requires its C terminus. Mol. Cell 2004, 16, 413-424.
61. Yee, K. S.; Vousden, K. H. Complicating the complexity of p53. Carcinogenesis 2005, 26, 1317-1322.
62. Sakaguchi, K.; Herrera, J. E.; Saito, S. i.; Miki, T.; Bustin, M.; Vassilev, A.; Anderson, C. W.; Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998, 12, 2831-2841.
63. Bode, A. M.; Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4, 793-805.
64. Ou, Y. -H.; Chung, P. -H.; Sun, T. -P.; Shieh, S. -Y. p53 C-Terminal Phosphorylation by CHK1 and CHK2 Participates in the Regulation of DNA-Damage-induced C-Terminal Acetylation. Mol. Biol. Cell 2005, 16, 1684-1695.
65. Olsson, A.; Manzl, C.; Strasser, A.; Villunger, A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ. 2007, 14, 1561-1575.
66. Krieg, A. J.; Hammond, E. M.; Giaccia, A. J. Functional Analysis of p53 Binding under Differential Stresses. Mol. Cell. Biol. 2006, 26, 7030-7045.
67. Meek, D. W. Mechanisms of switching on p53: a role for covalent modification? Oncogene 1999, 18, 7666-7675.
68. Krueger, K. E.; Srivastava, S. Posttranslational Protein Modifications: Current Implications for Cancer Detection, Prevention, and Therapeutics. Mol. Cell. Proteomics 2006, 5, 1799-1810.
69. Liu, L.; Scolnick, D. M.; Trievel, R. C.; Zhang, H. B.; Marmor-stein, R.; Halazonetis, T. D.; Berger, S. L. p53 Sites Acetylated In vitro by PCAF and p300 Are Acetylated In vivo in Response to DNA Damage. Mol. Cell. Biol. 1999, 19, 1202-1209.
70. Horn, H. F.; Vousden, K. H. Coping with stress: multiple ways to activate p53. Oncogene 2007, 26, 1306-1316.
71. Latonen, L.; Laiho, M. Cellular UV damage responses-functions of tumor suppressor p53. Biochim. Biophys. Acta 2005, 1755, 71-89.
72. Steven, R. G. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 2001, 268, 2773-2778.
73. Ljungman, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2000, 2, 208-225.
74. Laptenko, O.; Prives, C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 2006, 13, 951-961.
75. Gu, W.; Roeder, R. G. Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain. Cell 1997, 90, 595-606.
76. Lacroix, M.; Toillon, R. -A.; Leclercq, G. p53 and breast cancer, an update. Endocr. Relat. Cancer 2006, 13, 293-325.
77. Feng, L.; Lin, T.; Uranishi, H.; Gu, W.; Xu, Y. Functional Analysis of the Roles of Posttranslational Modifications at the p53 C Terminus in Regulating p53 Stability and Activity. Mol. Cell. Biol. 2005, 25, 5389-5395.
78. Helton, E. S.; Chen, X. p53 modulation of the DNA damage response. J. Cell. Biochem. 2007, 100, 883-896.
79. Zhao, L. Y.; Santiago, A.; Liu, J.; Liao, D. Repression of p53- mediated Transcription by Adenovirus E1B 55-kDa Does Not Require Corepressor mSin3A and Histone Deacetylases. J. Biol. Chem. 2007, 282, 7001-7010.
80. Tang, Y.; Luo, J.; Zhang, W.; Gu, W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apop-tosis. Mol. Cell 2006, 24, 827-839.
81. Knights, C. D.; Catania, J.; Giovanni, S. D.; Muratoglu, S.; Perez, R.; Swartzbeck, A.; Quong, A. A.; Zhang, X.; Beerman, T.; Pestell, R. G.; Avantaggiati, M. L. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J. Cell Biol. 2006, 173, 533-544.
82. Espinosa, J. M.; Emerson, B. M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 2001, 8, 57-69.
83. MacPherson, D.; Kim, J.; Kim, T.; Rhee, B. K.; Van Oostrom, C. T.; DiTullio, R. A.; Venere, M.; Halazonetis, T. D.; Bronson, R.; De Vries, A.; Fleming, M.; Jacks, T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 2004, 23, 3689-3699.
84. Chao, C.; Wu, Z.; Mazur, S. J.; Borges, H.; Rossi, M.; Lin, T.; Wang, J. Y. J.; Anderson, C. W.; Appella, E.; Xu, Y. Acetylation of Mouse p53 at Lysine 317 Negatively Regulates p53 Apoptotic Activities after DNA Damage. Mol. Cell. Biol. 2006, 26, 6859-6869.
85. Jones, P. A.; Baylin, S. B. The epigenomics of cancer. Cell 2007, 128, 683-692.
86. Klose, R. J.; Bird, A. P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 2006, 31, 89-97.
87. Freitag, M.; Selker, E. U. Controlling DNA methylation: many roads to one modification. Curr. Opin. Genet. Dev. 2005, 15, 191-199.
88. Xiong, Y.; Dowdy, S. C.; Podratz, K. C.; Jin, F.; Attewell, J. R.; Eberhardt, N. L.; Jiang, S. -W. Histone Deacetylase Inhibitors Decrease DNA Methyltransferase-3B Messenger RNA Stability and Down-regulate De novo DNA Methyltransferase Activity in Human Endometrial Cells. Cancer Res. 2005, 65, 2684-2689.
89. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6-21.
90. Lund, A. H.; van Lohuizen, M. Epigenetics and cancer. Genes Dev. 2004, 18, 2315-2335.
91. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature 2000, 403, 41-45.
92. Schrump, D. S.; Nguyen, D. M.; Kunst, T. E.; Hancox, A.; Figg, W. D.; Steinberg, S. M.; Pishchik, V.; Becerra, Y. Phase I study of sequential deoxyazacytidine/depsipeptide infusion in patients with malignancies involving lungs or pleura. Clin. Lung Cancer 2002, 4, 186-192.
93. Zhu, W. -G.; Hileman, T.; Ke, Y.; Wang, P.; Lu, S.; Duan, W.; Dai, Z.; Tong, T.; Villalona-Calero, M. A.; Plass, C.; Otterson, G. A. 5-Aza-2'-deoxycytidine Activates the p53/p21Waf1/Cip1 Pathway to Inhibit Cell Proliferation. J. Biol. Chem. 2004, 279, 15161-15166.
94. Peedicayil, J. The role of epigenetics in mental disorders. Indian J. Med. Res. 2007, 126, 105-111.
95. Weiser, T. S.; Guo, Z. S.; Ohnmacht, G. A.; Parkhurst, M. L.; Tong-On, P.; Marincola, F. M.; Fischette, M. R.; Yu, X.; Chen, G. A.; Hong, J. A.; Stewart, J. H.; Nguyen, D. M.; Rosenberg, S. A.; Schrump, D. S. Sequential 5-Aza-2'-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1. J. Immunother. 2001, 24, 151-161.
96. Claus, R.; Lubbert, M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003, 22, 6489-6496.
97. Primeau, M.; Gagnon, J.; Momparler, R. L. Synergistic antineo- plastic action of DNA methylation inhibitor 5-AZA-2'- deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int. J. Cancer 2003, 103, 177-184.
98. Chai, G.; Li, L.; Zhou, W.; Wu, L.; Zhao, Y.; Wang, D.; Lu, S.; Yu, Y.; Wang, H.; McNutt, M. A.; Hu, Y. G.; Chen, Y.; Yang, Y.; Wu, X.; Otterson, G. A.; Zhu, W. -G. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 2008, 3, e2445.
99. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1, 287-299.
100. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
101. Zhu, W. -G.; Otterson, G. A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anticancer Agents 2003, 3, 187-199.
102. Sandor, V.; Bakke, S.; Robey, R. W.; Kang, M. H.; Blagosklonny, M. V.; Bender, J.; Brooks, R.; Piekarz, R. L.; Tucker, E.; Figg, W. D.; Chan, K. K.; Goldspiel, B.; Fojo, A. T.; Balcerzak, S. P.; Bates, S. E. Phase I Trial of the Histone Deacetylase Inhibitor, Depsipep- tide (FR901228, NSC 630176), in Patients with Refractory Neoplasms. Clin. Cancer Res. 2002, 8, 718-728.
103. Marshall, J. L.; Rizvi, N.; Kauh, J.; Dahut, W.; Figuera, M.; Kang, M. H.; Figg, W. D.; Wainer, I.; Chaissang, C.; Li, M. Z.; Hawkins, M. J. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2002, 2, 325-332.
104. Abramson, J. S.; Shipp, M. A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005, 106, 1164-1174.
105. Vose, J. M.; Chiu, B. C. H.; Cheson, B. D.; Dancey, J.; Wright, J. Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma. Hematology 2002, 2002, 241-262.
106. Hideshima, T.; Bergsagel, P. L.; Kuehl, W. M.; Anderson, K. C. Advances in biology of multiple myeloma: clinical applications. Blood 2004, 104, 607-618.
107. Byrd, J. C.; Marcucci, G.; Parthun, M. R.; Xiao, J. J.; Klisovic, R. B.; Moran, M.; Lin, T. S.; Liu, S.; Sklenar, A. R.; Davis, M. E.; Lucas, D. M.; Fischer, B.; Shank, R.; Tejaswi, S. L.; Binkley, P.; Wright, J.; Chan, K. K.; Grever, M. R. A phase 1 and pharmacody-namic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105, 959-967.
108. Stadler, W. M.; Margolin, K.; Ferber, S.; McCulloch, W.; Thompson, J. A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 2006, 5, 57-60.
109. Li, L. -C.; Carroll, P. R.; Dahiya, R. Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment. J. Natl. Cancer Inst. 2005, 97, 103-115.
110. Pienta, K. J.; Smith, D. C. Advances in Prostate Cancer Chemotherapy: A New Era Begins. CA Cancer J. Clin. 2005, 55, 300-318.
111. Xiao, J. -J.; Huang, Y.; Dai, Z.; Sadee, W.; Chen, J.; Liu, S.; Mar-cucci, G.; Byrd, J.; Covey, J. M.; Wright, J.; Grever, M.; Chan, K. K. Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4, 21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8,7,6]-tricos-16- ene-3,6,9,22-pentanone] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines. J. Pharmacol. Exp. Ther. 2005, 314, 467-475.
112. Peart, M. J.; Tainton, K. M.; Ruefli, A. A.; Dear, A. E.; Sedelies, K. A.; O'Reilly, L. A.; Waterhouse, N. J.; Trapani, J. A.; Johnstone, R. W. Novel Mechanisms of Apoptosis Induced by Histone Deace-tylase Inhibitors. Cancer Res. 2003, 63, 4460-4471.